Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$69.30
-0.86-1.23%
At close: -
$69.21
-0.09-0.13%
After Hours: 4:29 PM EDT
Comments
Loading...
Novo Nordisk Analyst Ratings and Price Targets | NYSE:NVO | Benzinga
Novo Nordisk AS has a consensus price target of $116.57 based on the ratings of 11 analysts. The high is $160 issued by Cantor Fitzgerald on November 6, 2024. The low is $31 issued by BTIG on March 28, 2023. The 3 most-recent analyst ratings were released by BMO Capital, Cantor Fitzgerald, and BMO Capital on December 23, 2024, November 6, 2024, and October 17, 2024, respectively. With an average price target of $140.33 between BMO Capital, Cantor Fitzgerald, and BMO Capital, there's an implied 102.76% upside for Novo Nordisk AS from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
Cantor Fitzgerald
Argus Research
Argus Research
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Novo Nordisk
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/08/2025 | Buy Now | — | UBS | Jo Walton7% | — | Upgrade | Sell → Buy | Get Alert |
| 12/23/2024 | Buy Now | 51.71% | BMO Capital | Evan David Seigerman51% | $156 → $105 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/17/2024 | Buy Now | 125.4% | BMO Capital | Evan David Seigerman51% | $160 → $156 | Maintains | Outperform | Get Alert |
| 10/10/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/20/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/16/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 08/08/2024 | Buy Now | 131.18% | BMO Capital | Evan David Seigerman51% | $170 → $160 | Maintains | Outperform | Get Alert |
| 08/05/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 07/01/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/25/2024 | Buy Now | 135.52% | BMO Capital | Evan David Seigerman51% | $163 → $163 | Maintains | Outperform | Get Alert |
| 06/20/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 06/10/2024 | Buy Now | 131.18% | Argus Research | John Eade74% | $125 → $160 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/12/2024 | Buy Now | 135.52% | BMO Capital | Evan David Seigerman51% | → $163 | Initiates | → Outperform | Get Alert |
| 04/05/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $160 → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 131.18% | Cantor Fitzgerald | Louise Chen57% | $140 → $160 | Maintains | Overweight | Get Alert |
| 02/20/2024 | Buy Now | 102.28% | Cantor Fitzgerald | Louise Chen57% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/15/2024 | Buy Now | 102.28% | Cantor Fitzgerald | Louise Chen57% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/14/2024 | Buy Now | 102.28% | Cantor Fitzgerald | Louise Chen57% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 02/01/2024 | Buy Now | 80.61% | Argus Research | Jasper Hellweg69% | $115 → $125 | Maintains | Buy | Get Alert |
| 02/01/2024 | Buy Now | 102.28% | Cantor Fitzgerald | Louise Chen57% | $120 → $140 | Maintains | Overweight | Get Alert |
| 01/23/2024 | Buy Now | 73.39% | Morgan Stanley | Mark Purcell30% | → $120 | Initiates | → Overweight | Get Alert |
| 12/04/2023 | Buy Now | 66.16% | TD Cowen | Michael Nedelcovych71% | $105 → $115 | Maintains | Outperform | Get Alert |
| 12/01/2023 | Buy Now | 66.16% | Argus Research | John Eade74% | $110 → $115 | Maintains | Buy | Get Alert |
| 12/01/2023 | Buy Now | 73.39% | Cantor Fitzgerald | Louise Chen57% | → $120 | Initiates | → Overweight | Get Alert |
| 10/02/2023 | Buy Now | 58.94% | Argus Research | John Eade74% | → $110 | Initiates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | -55.21% | BTIG | Justin Zelin40% | $10 → $15.5 | Maintains | Buy | Get Alert |
| 12/12/2022 | Buy Now | 109.51% | TD Cowen | Michael Nedelcovych71% | $65 → $72.5 | Maintains | Outperform | Get Alert |
| 06/28/2022 | Buy Now | — | UBS | Michael Leuchten59% | — | Downgrade | Neutral → Sell | Get Alert |
| 06/07/2022 | Buy Now | — | JP Morgan | Richard Vosser44% | — | Upgrade | Neutral → Overweight | Get Alert |
| 05/31/2022 | Buy Now | — | Guggenheim | Seamus Fernandez61% | — | Upgrade | Neutral → Buy | Get Alert |
FAQ
What is the target price for Novo Nordisk (NVO) stock?
The latest price target for Novo Nordisk (NYSE:NVO) was reported by UBS on January 8, 2025. The analyst firm set a price target for $0.00 expecting NVO to fall to within 12 months (a possible -100.00% downside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novo Nordisk (NVO)?
The latest analyst rating for Novo Nordisk (NYSE:NVO) was provided by UBS, and Novo Nordisk upgraded their buy rating.
When was the last upgrade for Novo Nordisk (NVO)?
The last upgrade for Novo Nordisk AS happened on January 8, 2025 when UBS raised their price target to N/A. UBS previously had a sell for Novo Nordisk AS.
When was the last downgrade for Novo Nordisk (NVO)?
The last downgrade for Novo Nordisk AS happened on June 28, 2022 when UBS changed their price target from N/A to N/A for Novo Nordisk AS.
When is the next analyst rating going to be posted or updated for Novo Nordisk (NVO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on January 8, 2025 so you should expect the next rating to be made available sometime around January 8, 2026.
Is the Analyst Rating Novo Nordisk (NVO) correct?
While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a upgraded with a price target of $0.00 to $0.00. The current price Novo Nordisk (NVO) is trading at is $69.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.